Last reviewed · How we verify
IDP-118 Monad Taz Lotion
IDP-118 Monad Taz Lotion is a Small molecule drug developed by Bausch Health Americas, Inc.. It is currently in Phase 2 development. Also known as: Taz.
At a glance
| Generic name | IDP-118 Monad Taz Lotion |
|---|---|
| Also known as | Taz |
| Sponsor | Bausch Health Americas, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis (PHASE2)
- Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDP-118 Monad Taz Lotion CI brief — competitive landscape report
- IDP-118 Monad Taz Lotion updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI
Frequently asked questions about IDP-118 Monad Taz Lotion
What is IDP-118 Monad Taz Lotion?
IDP-118 Monad Taz Lotion is a Small molecule drug developed by Bausch Health Americas, Inc..
Who makes IDP-118 Monad Taz Lotion?
IDP-118 Monad Taz Lotion is developed by Bausch Health Americas, Inc. (see full Bausch Health Americas, Inc. pipeline at /company/bausch-health-americas-inc).
Is IDP-118 Monad Taz Lotion also known as anything else?
IDP-118 Monad Taz Lotion is also known as Taz.
What development phase is IDP-118 Monad Taz Lotion in?
IDP-118 Monad Taz Lotion is in Phase 2.
Related
- Manufacturer: Bausch Health Americas, Inc. — full pipeline
- Also known as: Taz
- Compare: IDP-118 Monad Taz Lotion vs similar drugs
- Pricing: IDP-118 Monad Taz Lotion cost, discount & access